0000000001182452

AUTHOR

K T C Brightson

showing 1 related works from this author

Oral antiseptics against coronavirus: in-vitro and clinical evidence

2021

Background Angiotensin converting enzyme II (ACE2) is the cellular receptor for SARS-CoV-2, so ACE2-expressing cells can act as target cells and are susceptible to infection. ACE2 receptors are highly expressed in the oral cavity so this may be a potential high-risk route for SARS-CoV-2 infection. Furthermore, the virus can be detected in saliva, even before COVID-19 symptoms appear, with the consequent high risk of virus transmission in asymptomatic/pre-symptomatic patients. Reducing oral viral load could lead to a lower risk of transmission via salivary droplets or aerosols and therefore contribute to the control of the pandemic. Aim To evaluate the available evidence testing the in vitro…

Microbiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtySalivaCoronavirus disease 2019 (COVID-19)coronavirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesMouthwashesCetylpyridiniumReviewmedicine.disease_causeLower riskViruslaw.inventionoral antisepticsRandomized controlled triallawInternal medicinemedicineHumansSalivaLetter to the EditorPandemicsPovidone-IodineCoronavirusMouthSARS-CoV-2Transmission (medicine)business.industryCOVID-19Hydrogen PeroxideGeneral MedicineViral LoadVirologyIn vitroCOVID-19 Drug TreatmentCoronavirusoral rinseInfectious DiseasesSystematic reviewClinical evidenceAnti-Infective Agents LocalCoronavirus InfectionsbusinessViral loadJournal of Hospital Infection
researchProduct